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Summary
Background.— Venous thromboembolism is a common and preventable cause of morbidity and
mortality in hospitalized patients. There is a lack of data on the distribution of risk factors and
prophylaxis practices in sub-Saharan Africa.
Abbreviations: ACCP, American College of Chest Physicians; CI, conﬁdence interval; DVT, deep vein thrombosis; ENDORSE,
Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting;
LMWH, low-molecular-weight heparin; PE, pulmonary embolism; TROMBUS, Table ronde de mobilisation pour le bon usage des
antithrombotiques (Round Table of Mobilization for the Best Use of Antithrombotics); UFH, unfractionated heparin; VTE, venous
thromboembolism.
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Aim.— To assess the prevalence of venous thromboembolism risk in hospitalized patients and
to determine the proportion of at-risk patients who receive prophylaxis.
Methods.— The study was a cross-sectional hospital-based survey. On the basis of the global
ENDORSE methodology, patients aged≥ 40 years admitted to a medical ward or those aged≥ 18
years admitted to a surgical ward were assessed for risk of venous thromboembolism by hospital
chart review. Distribution of risk factors and coverage of prophylaxis in at-risk patients were
determined using the 2004 American College of Chest Physicians evidence-based consensus
guidelines.
Results.— From October to November 2008, 520 patients (278 medical; 242 surgical) were
enrolled in 12 hospitals across Senegal. Two hundred and ninety-eight (57%) were at risk of
venous thromboembolism; 152 (57.4%) medical patients and 146 (60.3%) surgical patients.
Among those at risk, 48 (31.6%) medical patients and 52 (35.6%) surgical patients received a
prescription for prophylaxis. Among patients without contraindication to anticoagulants, 33.8%
(46/136) on medical wards and 37.5% (48/128) on surgical wards received prophylaxis.
Conclusion.— The risk of venous thromboembolism was frequent in hospitalized patients in
Senegal but only a few received the recommended prophylaxis. There is a need to implement
a programme to improve venous thromboembolism awareness and prophylaxis.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— La maladie thromboembolique veineuse est une cause fréquente mais évitable de
décès et de morbidité hospitalière. En Afrique sub-saharienne, les données sur les facteurs de
risque et la prophylaxie sont rares.
Objectif.— Évaluer le risque de maladie thromboembolique veineuse chez les patients hospi-
talisés au Sénégal et déterminer la proportion recevant une prophylaxie.
Méthodologie.— Enquête transversale hospitalière. Compte tenu de la méthodologie de
l’enquête Endorse, les patients âgés de 40 ans ou plus admis en milieu médical et ceux de 18
ans ou plus en milieu chirurgical ont été étudiés à partir de leur dossier hospitalier. L’évaluation
du risque thromboembolique veineux et la détermination de la prescription de prophylaxie ont
été faites selon les critères ACCP-2004.
Résultats.— D’octobre à novembre 2008, 520 patients (278 en médecine et 242 en chirurgie) ont
été inclus dans 12 hôpitaux au Sénégal. Deux cent quatre-vingt-dix-huit, 298 (57 %) présentaient
un risque de maladie thromboembolique veineuse dont 152 (57,4 %) en médecine et 146 (60,3 %)
en chirurgie. Parmi les patients à risque, 48 (31,6 %) en médecine et 52 (3,6 %) en chirurgie
ont rec¸u une prescription de prophylaxie. Chez les patients à risque ne présentant pas de
contre-indication aux anticoagulants, la proportion de prophylaxie était de 33,8 % (46/136) en
médecine et 37,5 % (48/128) en chirurgie.
Conclusion.— Le risque de maladie thromboembolique veineuse est très fréquent dans les hôpi-
taux sénégalais. Peu de patients rec¸oivent la prophylaxie adaptée. Il est nécessaire de mettre
en place des programmes pour améliorer la connaissance de la maladie et de sa prophylaxie.
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ackground
TE is a common complication that affects patients hos-
italized for a variety of medical and surgical conditions.
t contributes to longer duration of hospitalization stay,
orbidity and mortality, with PE accounting for 5—10% of
eaths in hospitalized patients [1]. VTE is often asymp-
omatic, misdiagnosed and unrecognized at death, as there
s a lack of routine postmortem examinations. These factors
re thought to result in a marked underestimation of VTE
ncidence [2].
VTE in hospitalized patients is often thought of as a
onsequence of surgery, as major surgery is a risk fac-
or, but medical patients also are at risk. Non-surgical
atients account for 70—80% of fatal PE cases and 50—70%
f symptomatic thromboembolic events [3]. In an 8-month
t
p
d
as droits réservés.
rospective screening study, DVT was detected by ultra-
ound in 33% of adults admitted to a medical intensive care
nit [4]. The high incidence of DVT in medical patients
nd the high percentage of patients with VTE who are
symptomatic underscore the importance of identifying and
ssessing the risk of VTE in hospital patients, so that pro-
hylactic strategies can be implemented [5]. Up to 10% of
ospital deaths are caused by PE, suggesting that there is
oom for improvement in identifying patients at risk of VTE
nd providing VTE prophylaxis [3].
Risk factors for VTE are well established. Overall, VTE
isk should be perceived as the combined result of consti-
utional risk factors and the added risk attributable to the
atient’s current medical situation and/or surgical proce-
ure [6]. The most common personal risk factors include
ge > 75 years, cancer (history or current), history of VTE,
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obesity, varicose veins, hormone therapy (antiandrogen or
oestrogen), chronic heart failure and chronic respiratory
failure [7]. Medical conditions that increase a patient’s risk
of VTE include congestive heart failure, severe respiratory
disease, acute medical illness leading to immobility and bed
conﬁnement, additional risk factors such as active cancer or
previous VTE, and admission to critical care units. [1]. Sur-
gical patients undergoing knee or hip surgery are at highest
risk of VTE. Other surgeries, such as trauma or major injury,
may also expose patients to a moderate-to-high risk of VTE
[1].
A recent survey (ENDORSE) [8] has provided data on
the prevalence of VTE risk and prophylaxis in 32 countries:
almost 53% of hospitalized patients were found to be at risk
of VTE according to the 2004 ACCP guidelines [3]. There
was huge variation in the prevalence of VTE risk between
countries (35.6—72.6%) and between types of wards (64% in
surgical wards; 41% in medical wards) [8]. The overall pro-
portions of patients at risk of VTE who received adequate
prophylaxis were low (58.5% in surgical patients; 39.5% in
medical patients). Of note, no sub-Saharan African country
was included in this global ENDORSE study.
A possible effect of race and ethnicity on the incidence
of VTE has been reported [9]. Some authors have suggested
that a higher prevalence of VTE in Caucasians is due to the
fact that factor V Leiden is more prevalent in Caucasian than
in African-American or Asian populations [10]. However, a
recent review of the subject by White and Keenan concluded
that African-American patients have a signiﬁcantly higher
incidence of ﬁrst-time VTE exposure and are more likely to
manifest a PE compared with other racial groups, although
the incidence of recurrent VTE is similar across racial groups
[9].
There is a relative paucity of studies on the prevalence
of VTE and its associated risk factors in sub-Saharan African
populations. A retrospective analysis of nearly 1000 post-
mortem reports in Nigeria found a prevalence of PE of 2.9%
[11]. The most frequent risk factors for PE were malignancy
(38%) and immobility for > 4 days (28%). To our knowledge,
this is the most recent study on VTE risk in an African pop-
ulation.
Evidence-based consensus guidelines for VTE prophylaxis
have been available for almost 20 years [12]. The ACCP
guidelines recommend prophylaxis for patients at moderate-
to-high risk of VTE, using either mechanical prophylaxis
and/or pharmacological prophylaxis (LMWH, fondaparinux
and UFH) [1]. New oral anticoagulants are available in
western countries, even if they have not yet shown their
superiority and safety against LMWH in diverse situations.
However, prophylaxis with these new oral anticoagulants
must only be given in labelled indications (total hip arthro-
plasty and total knee arthroplasty).
Despite this evidence and the guidelines, physicians often
fail to use this important therapy in a variety of high-risk
situations, including the perioperative period, during critical
illness and among other high-risk medical patients [2].
On the basis of the ENDORSE study methodology [8], a
multidisciplinary group of Senegalese experts (the TROM-
BUS committee) conducted a country-wide assessment of
the prevalence of VTE risk and VTE prophylaxis coverage
in the acute-care setting in Senegal. The aim of the survey
was to acquire accurate prospective data on VTE risk and
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TE prophylaxis in developing countries to support national
isease management.
ethods
he methodology was adapted from the ENDORSE study [8].
ospitals were considered eligible for enrolment if they con-
ained more than 50 beds: in Senegal, this amounted to
8 functioning hospitals and private clinics with a total of
084 eligible beds. Stratiﬁed sampling was done to ensure
hat at least two hospitals were included from each of the
our geographic zones identiﬁed in the country. Included
ospitals were randomly selected using a random table. At
ospital level, wards were eligible if they were occupied by
cute medical and surgical patients. All eligible wards within
nrolled hospitals were included in the study.
To comply with the international ENDORSE study, the
ollowing wards were not included: psychiatric; paedi-
tric; palliative; maternity and obstetric; neonatal; burns
nits; ophthalmologic; ear, nose and throat; dermatologic;
lcohol/drug treatment; rehabilitation; accident and emer-
ency.
In eligible wards, the inclusion criteria for patients were
he same as for the ENDORSE study [8]: age≥ 40 years in
edical wards or age≥ 18 years in surgical wards. In medi-
al wards, eligible patients included those who were acutely
ll; in surgical wards, eligible patients included those who
ad undergone a surgical intervention requiring general or
pidural anaesthesia for at least 45mins or who were admit-
ed due to a major trauma.
Patients were not eligible if they would have normally
een admitted to an ineligible ward, if they were admitted
or treatment of VTE or for a minor procedure, if their chart
as unavailable or missing or if they refused to give informed
onsent. All patients in all eligible wards were screened.
ata collection
fter obtaining informed consent from patients, data were
ollected using a standardized questionnaire adapted from
he ENDORSE study case report form. Data collected
ncluded: patient demographics; date of admission; medical
istory, including risk factors for VTE; surgical intervention;
isk factors for bleeding during hospitalization; risk factors
or VTE manifested immediately before admission or in the
rst 14 days of hospitalization; type, dose and frequency of
TE prophylaxis and start or stop date; presence or absence
f anticoagulation therapy and start or stop date; and condi-
ion of patient upon discharge.
Enrolled patients were assessed for VTE risk as per the
CCP 2004 guidelines ([8], web tables 1 and 2). Patients
onsidered as being at risk of VTE were classiﬁed as being
t moderate, high or highest risk.
Types and use of VTE prophylaxis received by patients
ere recorded from their hospital charts. Evaluation of
rophylaxis was done according to both the type and the
ose prescribed. Patients were classiﬁed as receiving pro-y a physician during hospitalization. Prophylaxis methods
ncluded antithrombotic drugs (heparins, vitamin K antago-
ists, direct thrombin inhibitors, factor Xa inhibitors) given
496 S.A. Bâ et al.
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Tigure 1. Selection of patients.
or prevention of DVT and PE or mechanical prophylaxis
intermittent pneumatic compression, graduated compres-
ion stockings, foot pump).
Clinical situations deﬁned as contraindications to anti-
oagulant prophylaxis were: intracranial haemorrhage;
epatic impairment; bleeding at hospital admission; active
astroduodenal ulcer; or known bleeding disorder [13].
tatistical analysis
o assess the true occurrence of VTE risk at 10%with amargin
f error of 4%, a minimum of 216 patients per analysis group
ere required.
Collected data were double checked and double entered
nto Epi Info software, version 6.04. Quantitative data were
ummarized using the median. Categorical data were sum-
arized using number and percentage. Ninety-ﬁve percent
I were calculated.
The proportion of at-risk patients was calculated as
he number of patients at moderate, high or highest
isk of VTE/number of patients included. The proportion
1
i
w
df patients receiving prophylaxis was calculated as the
umber of patients who received a prescription for prophy-
axis/number of patients at risk of VTE.
The study was approved by the Senegalese Ethics Com-
ittee (Ministry of Health).
esults
etween October 2008 and November 2008, 943 patients
ere screened and of these 520 were enrolled for VTE
isk assessment in 12 hospitals across Senegal; 306 of these
atients were enrolled in Dakar and 214 from the surround-
ng regions. The number of beds assessed and the reasons
or exclusion of patients are shown in Fig. 1. Demographics
nd reasons for admission of patients are shown in Table 1.
he median age of patients on medical wards was 62 years,
50 (54.0%) were men and the median duration of hospital-
zation was 7 days. The median age of patients on surgical
ards was 49 years, 155 (55.8%) were men and the median
uration of hospitalization was 8 days.
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VTE prophylaxis coverage in patients hospitalized for med-Figure 2. Proportion of medical patients (A) and surgical patients
(B) at risk of venous thromboembolism.
More than 40% of medical patients but less than 20%
of surgical patients had at least one risk factor for VTE
prior to admission (Table 2). The most prevalent VTE risk
factor present at admission for both groups of patients was
long-term immobility. The most prevalent risk factors among
women differed between groups: among the 128 female
medical patients the most common VTE risk factor was con-
traceptive use (n = 5, 3.9%), while among the 87 female
surgical patients, themost common VTE risk factor was preg-
i
w
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ancy (n = 6, 6.9%). Post admission, the most prevalent risk
actors for VTE in both groups were immobility with bath-
oom privileges and complete immobilization.
Of the 520 enrolled patients, 298 (57%) were identiﬁed
o be at risk of VTE according to the ACCP guidelines [3]. For
atients in medical wards, 152 (57.4%, 95% CI 48.8—60.5%)
ere deemed to be at risk of VTE according to ACCP guide-
ines, 38% due to heart failure or severe respiratory disease
nd 17% due to immobility or reduced mobility combined
ith at least one other risk factor (Fig. 2A).
The proportion of patients in medical wards, regard-
ess of risk, who received prophylaxis was 20.9% (n = 58);
f those deemed to be at risk for VTE, the proportion
ho received prophylaxis was 31.6% (n = 48); 10 patients
eceived prophylaxis despite a lack of indication. Nearly
0% of patients at risk in cardiovascular wards were given
rophylaxis, whereas only 11% of patients at risk due to
nfectious diseases received prophylaxis (Fig. 3). No patients
n the intensive care units or neurology wards who were at
isk received prophylaxis. The only anticoagulant prescribed
n all cases was the LMWH enoxaparin, at a median dose of
0mg per day.
Among surgical patients, 146 (60.3%, 95% CI 54.2—66.5%)
ere considered to be at risk of VTE and requiring prophy-
axis, the majority (33%) having moderate risk (Fig. 2B).
verall, 86 patients (35.5%) received VTE prophylaxis;
f those who were at risk, 52 (35.6%) received effec-
ive prophylaxis. Thirty-four patients received prophylaxis
espite not being considered at risk according to the 2004
CCP guidelines. All patients (n = 18) who had undergone
ip surgery received prophylaxis, whereas only 36.4% of
atients with head trauma received prophylaxis. The high-
st coverage of prophylaxis in surgical wards was found on
rthopaedic wards, with 82.3% of at-risk patients receiving
rophylaxis, followed by surgical intensive care units, with
0.0% of patients receiving prophylaxis (Fig. 3). None of the
atients in neurology or urology units received prophylaxis
or VTE. Enoxaparin 40mg once daily represented 94% of all
rescriptions for prophylaxis for VTE. Enoxaparin 20mg once
aily (2.5%) and enoxaparin 60mg once daily (3.5%) were the
ther prescriptions.
Overall, 51 patients (9.8%) had a contraindication to
harmacological prophylaxis (Table 3). The most common
ontraindications were hepatic impairment in nine (41%)
edical patients and bleeding upon admission in 14 (48%)
urgical patients. Among the population at risk of VTE, 16
10.5%) medical patients and 18 (12.3%) surgical patients
ere considered to have a contraindication to pharmaco-
ogical prophylaxis. Among patients at risk of VTE who had
o contraindication to anticoagulant therapy, the propor-
ions who received prophylaxis were 33.8% (46/136; CI 95%
5.9—41.8%) in the medical wards and 37.5% (48/128; CI 95%
9.1—45.9%) in the surgical wards.
iscussion
his study is the ﬁrst survey to measure VTE risk and use ofcal or surgical conditions in West Africa. The methodology
as based on the ENDORSE study methodology [8], with
inor adaptations. Our survey showed that more than half of
498 S.A. Bâ et al.
Table 1 Characteristics of patients and reasons for admission to medical and surgical wards.
Medical patients
(n = 278)
Surgical patients
(n = 242)
Age (years) 62 (40—90) 49 (18—90)
Men 150 (54.0) 155 (64.0)
Length of hospitalization (days) 7 8
Hospitalized > 10 days 89 (32.0) 100 (41.3)
Reason for admission to medical ward
Acute heart failure 42 (15.1)
Other cardiovascular disease 65 (23.4)
Acute non-infectious respiratory diseases 12 (4.3)
Pulmonary infection 43 (15.5)
Infection (non-respiratory) 37 (13.3)
Ischaemic stroke 18 (6.5)
Cerebral haemorrhage 6 (2.2)
Haematological diseases 10 (3.6)
Malignancy (active) 13 (4.7)
Rheumatological or inﬂammatory disease 13 (4.7)
Neurological diseases 19 (6.8)
Renal diseases 14 (5.0)
Endocrine/metabolic disease 43 (15.5)
Other medical condition 18 (6.5)
Reason for admission to surgical ward
Major trauma 81 (33.5)
Surgery with anaesthesia > 45minutes 162 (66.9)
Under observation 27 (11.2)
Awaiting surgery 52 (21.5)
Data are median, median (range) or number (%); percentages may add up to more than 100% as patients could have more than one
medical condition.
Figure 3. Proportion of at-risk patients receiving prophylaxis. ICU: intensive care unit.
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Table 2 Risk factors for venous thromboembolism.
Medical patients
(n = 278)
Surgical patients
(n = 242)
Before admission
Patients with≥ 1 risk factor present before admission 123 (44.2) 41 (16.9)
Previous venous thromboembolism 4 (1.4) 0
Obesity 21 (7.5) 12 (5.0)
Varicose veins or venous insufﬁciency 2 (0.7) 1 (0.4)
Thrombophilia 1 (0.4) 1 (0.4)
Hormone replacement therapy 1 (0.8)a 1 (1.1)b
Chronic pulmonary disease 42 (15.1) 4 (1.7)
Long-term immobility 52 (18.7) 13 (5.4)
Pregnancy (within 3 months) 2 (1.6)a 6 (6.9)b
Contraceptives 5 (3.9)a 3 (3.4)b
Chronic heart failure 32 (11.5) 4 (1.7)
Post admission
Admitted to critical or intensive care unit 1 (0.4) 3 (1.2)
Central venous catheter 0 1 (0.4)
Mechanical ventilation 0 1 (0.4)
Immobile with bathroom privileges 38 (13.7) 15 (6.2)
Complete immobilization 35 (12.6) 14 (5.8)
Cancer therapy 2 (0.7) 3 (1.2)
Heparin-induced thrombocytopoenia 0 0
Data are number (%).
a n = 128 women.
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rn = 87 women.
all hospitalized patients examined in eligible wards were at
risk of VTE, according to the 2004 ACCP risk deﬁnition. Surgi-
cal patients were slightly more at risk than medical patients
(60.3% vs 57.4%). These ﬁndings are similar to that of a study
examining VTE risk worldwide [8].
However, among all patients at risk, less than a third of
medical patients and just over a third of surgical patients
were receiving prophylaxis. A large multinational study
found rates ranging anywhere from 4 to 80% and from 0.4
to 94% for any type of prophylaxis among at-risk medical
and surgical patients, respectively [8]. Within Senegal, at
the various hospitals examined, rates of coverage for at-risk
patients varied greatly, from 0 to 50% and from 0 to 83% for
medical and surgical patients, respectively.
Prophylaxis in hospitalized medically ill patients was very
low in our survey. Less than one third of patients at risk
t
T
t
Table 3 Contraindications to pharmacological venous thromb
Medic
(n = 22
Intracranial haemorrhage 6 (27.
Unknown bleeding syndrome 2 (9.1
Hepatic impairment 9 (40.
Bleeding upon admission 2 (9.1
Active duodenal ulcer 3 (13.
Data are number (%).eceived a prescription for prophylaxis, regardless of dura-
ion. This result is consistent with that reported in the
ubgroup analysis of medically ill patients from the ENDORSE
tudy: Bergmann et al. concluded that ACCP-recommended
rophylaxis was underused worldwide in the medical patient
opulation and was provided to < 40% of those at risk [14].
his under usage of VTE prophylaxis in medical wards may
eﬂect a low level of perception of the risk of VTE among
ome hospital physicians, combined with a lack of awareness
f the beneﬁts of VTE prophylaxis [15].
Surprisingly, prophylaxis coverage in surgical patients was
lso low in our survey. Less than 40% of at-risk VTE patients
eceived prophylaxis, which was not statistically different
o the rate of usage of prophylaxis in medical patients.
his is in contrast to the ENDORSE global survey, where
he rate of prophylaxis was reportedly signiﬁcantly higher
oembolism prophylaxis.
al patients
)
Surgical patients
(n = 29)
3) 3 (10.3)
) 2 (6.9)
9) 9 (31.0)
) 14 (48.3)
6) 1 (3.4)
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[7] Turpie AG. Thrombosis prophylaxis in the acutely ill medical
patient: insights from the prophylaxis in MEDical patients with00
n surgical patients, ranging from 50 to 88% [8]. In our sur-
ey, prophylaxis coverage was higher in orthopaedic patients
han in other surgical patients, suggesting that orthopaedic
urgeons are more aware of VTE risk and are more convinced
bout the necessity of VTE prophylaxis than other surgeons.
survey in Togo has found that only 16% of anaesthetists
nd surgeons considered that VTE was as common in their
ountry as in western countries [16]. There is an urgent need
or awareness and training of physicians regarding the bur-
en of VTE. In the context of low-income countries without
ocial security or insurance coverage, cost of drugs may have
mpacted negatively on the prescription of VTE prophylaxis
nd patients’ adherence to treatment. In the participating
ospitals, patients pay for the drugs themselves; the average
rice of one syringe of LMWH is ∼D 4.5.
Only one anticoagulant was prescribed, namely enoxa-
arin. Despite the fact that almost 10% of patients
ad a contraindication to pharmacological prophylaxis, no
echanical prophylaxis was used to prevent VTE. It should
e noted that some local practices in surgical wards are con-
idered as mechanical prophylaxis (early mobilization and
horter hospital stays).
By excluding medical patients aged < 40 years, we may
ave excluded some potential groups who are known to be
t risk for VTE, such as those with poststreptococcal car-
iopathy, which is known to be more frequent in patients
ged 15—25 years and is also known to lead frequently to VTE
17]. Some other risk factors frequent in the African popula-
ion, such as sickle cell disease [18], have not been captured
n our study. This may have led to an underestimation of
he proportion of patients at risk who need VTE prophylaxis.
iven the cross-sectional design of this study, only the qual-
ty of treatment up to the date of the survey was recorded
nd assessed. Adherence to prophylaxis through to the end
f a patient’s hospital stay was not recorded, which may
ave led to an overestimation of prophylaxis rates.
Means to improve VTE prophylaxis coverage should
nclude increasing physicians’ awareness through train-
ng and the implementation of procedures to assess VTE
isk during hospitalization, along with the application of
vidence-based guidelines for VTE prophylaxis and treat-
ent in both medical and surgical patients [5]. Three types
f strategy may be used to improve VTE risk assessment
nd the use of VTE prophylaxis when it is warranted [5]:
isk assessment scoring systems; risk recognition systems;
nd prophylaxis default systems. Risk assessment scoring
ystems categorize a patient’s risk based on their risk fac-
ors for VTE [5]. It should be noted that there are no
ocal guidelines for the prevention of VTE in Senegal. Con-
idering that VTE is a serious clinical situation that may
ead to patient death, VTE is usually asymptomatic and
TE prevention is more cost-effective than treatment, we
o recommend the assessment of VTE risk (using a risk
odel assessment form, locally adapted) for all hospitalized
atients at admission and during hospitalization. Patients
ound to be at risk for VTE will be candidates for the most
dequate thromboprophylaxis (taking socioeconomics into
onsideration). Other means of VTE prevention, such as
echanical prophylaxis, are scarce in our country; the low
evel of education of patients in our setting might be a
ajor constraint regarding their utilization in a public health
pproach.S.A. Bâ et al.
onclusion
TE is a major clinical concern with a substantial risk of
orbidity and mortality in patients hospitalized for acute
edical and surgical illnesses. This hospital-based country-
ide study in Senegal shows that large proportions of
edical and surgical patients are at risk of VTE but that
he recommended VTE prophylaxis is not prescribed in the
ajority of cases. A nationwide strategy to assess patients at
TE risk, along with measures to educate and inform physi-
ians about appropriate forms of VTE prophylaxis, should be
ndertaken in Senegal. Efforts need to be made by all levels
f stakeholders (Ministry of Health, pharmaceutical industry,
hysicians) to increase access to high quality medications
nd other appropriate interventions at the appropriate
rices, in order to ensure the safe and widespread use of
TE prophylaxis.
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